Finance

Lists
DSGN:NASDAQ
Design Therapeutics Inc
$14.83
+3.06%
(+0.44) 1D
$14.83
0.00% (0.00)
After hours
Closed: Aug 14, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DSGN...
Open
$14.41
High
$14.86
Low
$14.02
Mkt. cap
928.09M
Avg. vol.
584.48K
Volume
259.84K
52-wk high
$17.25
52-wk low
$4.68
EPS
-$1.18
Beta
1.63
Shares outstanding
62.58M
No. of employees
55
Open
$14.41
High
$14.86
Low
$14.02
Mkt. cap
928.09M
Avg. vol.
584.48K
Volume
259.84K
52-wk high
$17.25
52-wk low
$4.68
EPS
-$1.18
Beta
1.63
Shares outstanding
62.58M
No. of employees
55
News stories
From web sources and news partners
About Design Therapeutics Inc
CEO-
Employees55
Founded2017
HeadquartersCarlsbad, California, United States
SectorBiotechnology
Websitedesigntx.com
Analyst ratings
Based on 5 analysts giving stock ratings to DSGN in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for DSGN in the last 3 months.
Highest
Current $14.83
$40.54 (+173.36%)
Average
$24.71 (+66.62%)
Lowest
$20.00 (+34.86%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Cantor Fitzgerald
Buy
Maintained
$40.54
+173.4%
08/05/2026
Adam Vogel
Craig-Hallum
Buy
Maintained
$22.00
+48.3%
08/04/2026
Leonid Timashev
RBC Capital
Buy
Maintained
$20.00
+34.9%
08/03/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
$21.00
+41.6%
06/15/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$20.00
+34.9%
05/27/2026
Faisal Khurshid
Jefferies
Buy
Initiated
$15.00
+1.1%
03/15/2026
Luca Issi
RBC Capital
Buy
Reiterated
$14.00
-5.6%
03/09/2026
Last report
Aug 3, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.32 / -$0.34
+7.06%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
14.59M
13.42M
14.38M
16.39M
Cost of revenue
14.59M
13.42M
14.38M
16.39M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.72M
4.74M
5.33M
5.79M
Operating expense
4.72M
4.74M
5.33M
5.79M
Total operating expenses
19.31M
18.17M
19.71M
22.18M
Operating income
-19.31M
-18.17M
-19.71M
-22.18M
Other non operating income
-
-
-
-
EBT including unusual items
-17.00M
-16.00M
-17.64M
-20.16M
EBT excluding unusual items
-17.00M
-16.00M
-17.64M
-20.16M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-17.00M
-16.00M
-17.64M
-20.16M
Net profit margin
-
-
-
-
Earnings per share
-0.30
-0.27
-0.29
-0.32
Interest and investment income
2.31M
2.17M
2.07M
2.01M
Interest expense
-
-
-
-
Net interest expenses
2.31M
2.17M
2.07M
2.01M
Depreciation and amortization charges
-
-
-
-
EBITDA
-19.16M
-18.01M
-19.55M
-22.03M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps